Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9BZE1
UPID:
RM37_HUMAN
Alternative names:
39S ribosomal protein L2, mitochondrial; 39S ribosomal protein L37, mitochondrial
Alternative UPACC:
Q9BZE1; Q96Q67; Q9BWR1; Q9P0P3
Background:
The Large ribosomal subunit protein mL37, also known as 39S ribosomal protein L2 and L37, mitochondrial, plays a crucial role in mitochondrial protein synthesis. Its involvement in the assembly of the mitochondrial ribosome underscores its importance in cellular energy metabolism.
Therapeutic significance:
Understanding the role of Large ribosomal subunit protein mL37 could open doors to potential therapeutic strategies.